 Receptors, Tumor Necrosis Factor
"Receptors, Tumor Necrosis Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
| Descriptor ID |
D018124
|
| MeSH Number(s) |
D12.776.543.750.705.852.760
|
| Concept/Terms |
Receptors, Tumor Necrosis Factor- Receptors, Tumor Necrosis Factor
- Receptors, Cachectin
- Tumor Necrosis Factor Receptors
- TNF Receptor
- Receptor, TNF
- TNF Receptors
- Tumor Necrosis Factor Receptor
- Cachectin Receptors
- Receptors, TNF
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor".
- Receptors, Tumor Necrosis Factor
- B-Cell Activation Factor Receptor
- B-Cell Maturation Antigen
- CD40 Antigens
- Etanercept
- fas Receptor
- Glucocorticoid-Induced TNFR-Related Protein
- Ki-1 Antigen
- Lymphotoxin beta Receptor
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Ectodysplasin
- Receptors, OX40
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, Tumor Necrosis Factor, Member 14
- Receptors, Tumor Necrosis Factor, Member 25
- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Type II
- Transmembrane Activator and CAML Interactor Protein
- Tumor Necrosis Factor Decoy Receptors
- Tumor Necrosis Factor Receptor Superfamily, Member 7
- Tumor Necrosis Factor Receptor Superfamily, Member 9
- TWEAK Receptor
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 | | 1996 | 4 | 0 | 4 | | 1997 | 3 | 1 | 4 | | 1998 | 4 | 3 | 7 | | 1999 | 5 | 6 | 11 | | 2000 | 8 | 2 | 10 | | 2001 | 6 | 2 | 8 | | 2002 | 3 | 5 | 8 | | 2003 | 6 | 3 | 9 | | 2004 | 6 | 4 | 10 | | 2005 | 3 | 2 | 5 | | 2006 | 5 | 1 | 6 | | 2007 | 1 | 1 | 2 | | 2008 | 0 | 1 | 1 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 2 | 1 | 3 | | 2012 | 2 | 2 | 4 | | 2013 | 3 | 5 | 8 | | 2014 | 0 | 2 | 2 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor" by people in Profiles.
-
Epeldegui M, Chang D, Lee J, Magpantay LI, Borok M, Bukuru A, Busakhala N, Godfrey C, Hosseinipour MC, Kang M, Kanyama C, Langat D, Mngqibisa R, Mwelase N, Nyirenda M, Samaneka W, Hoagland B, Campbell TB, Mart?nez-Maza O, Krown SE. Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings. J Acquir Immune Defic Syndr. 2023 10 01; 94(2):165-173.
-
Holmberg R, Robinson M, Gilbert SF, Lujano-Olazaba O, Waters JA, Kogan E, Velasquez CLR, Stevenson D, Cruz LS, Alexander LJ, Lara J, Mu EM, Camillo JR, Bitler BG, Huxford T, House CD. TWEAK-Fn14-RelB Signaling Cascade Promotes Stem Cell-like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse. Mol Cancer Res. 2023 02 01; 21(2):170-186.
-
Ni?o KE, Pietras EM. TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis. Cancer Discov. 2022 12 02; 12(12):2724-2726.
-
Liu S, Sirohi K, Verma M, McKay J, Michalec L, Sripada A, Danhorn T, Rollins D, Good J, Gorska MM, Martin RJ, Alam R. Optimal identification of human conventional and nonconventional (CRTH2-IL7Ra-) ILC2s using additional surface markers. J Allergy Clin Immunol. 2020 08; 146(2):390-405.
-
Moua P, Checketts M, Xu LG, Shu HB, Reyland ME, Cusick JK. RELT family members activate p38 and induce apoptosis by a mechanism distinct from TNFR1. Biochem Biophys Res Commun. 2017 09 09; 491(1):25-32.
-
Pennock ND, Kedl JD, Kedl RM. T Cell Vaccinology: Beyond the Reflection of Infectious Responses. Trends Immunol. 2016 Mar; 37(3):170-180.
-
Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis. J Manag Care Spec Pharm. 2014 Jul; 20(7):657-67.
-
Prieto-Moure B, Carab?n-Reda?o A, Aliena-Valero A, Cejalvo D, Toledo AH, Flores-Bellver M, Mart?nez-Gil N, Toledo-Pereyra LH, Lloris Cars? JM. Allopurinol in renal ischemia. J Invest Surg. 2014 Oct; 27(5):304-16.
-
Maruotti N, D'Onofrio F, Neve A, Santoro N, Corrado A, Cantatore FP. Anti-TNF-a and risk of infections: the experience in one center. Panminerva Med. 2014 Mar; 56(1):31-4.
-
Wang H, Zheng HJ, Wang Z, Bai H, Carpenter JF, Chen S, Fang WJ. Formation of protein sub-visible particles during vacuum degassing of etanercept solutions. Int J Biol Macromol. 2014 May; 66:151-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|